标题
Targeted therapy of brain metastases: latest evidence and clinical implications
作者
关键词
-
出版物
Therapeutic Advances in Medical Oncology
Volume 9, Issue 12, Pages 781-796
出版商
SAGE Publications
发表日期
2017-11-15
DOI
10.1177/1758834017736252
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
- (2017) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
- (2017) Michael A Davies et al. LANCET ONCOLOGY
- A Patient With Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib
- (2017) Jonathan W. Riess et al. Journal of the National Comprehensive Cancer Network
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib
- (2016) E. Larkins et al. CLINICAL CANCER RESEARCH
- Brain Metastasis Responsive to Pazopanib in Renal Cell Carcinoma: A Case Report and Review of the Literature
- (2016) Megan E. Gooch et al. Clinical Genitourinary Cancer
- Osimertinib: First Global Approval
- (2016) Sarah L. Greig DRUGS
- Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non–Small-Cell Lung Cancer
- (2016) Shirish M. Gadgeel et al. JOURNAL OF CLINICAL ONCOLOGY
- Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
- (2016) Rachel A. Freedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
- (2016) Sai-Hong Ignatius Ou et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
- (2016) Dong-Wan Kim et al. LANCET ONCOLOGY
- Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
- (2016) Alice T Shaw et al. LANCET ONCOLOGY
- BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy
- (2016) Mudit Chowdhary et al. OncoTargets and Therapy
- Radiosensitization by BRAF inhibitor therapy--mechanism and frequency of toxicity in melanoma patients
- (2015) M. Hecht et al. ANNALS OF ONCOLOGY
- LBA4 * EVALUATION OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR BRIGATINIB [AP26113] IN PATIENTS (PTS) WITH ALK+ NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES
- (2015) D. Kerstein et al. ANNALS OF ONCOLOGY
- Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer
- (2015) Gayathri Nagaraj et al. BREAST CANCER RESEARCH AND TREATMENT
- Activity of T-DM1 in Her2-positive breast cancer brain metastases
- (2015) Rupert Bartsch et al. CLINICAL & EXPERIMENTAL METASTASIS
- FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
- (2015) S. Khozin et al. CLINICAL CANCER RESEARCH
- 3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement
- (2015) A. Varga et al. EUROPEAN JOURNAL OF CANCER
- 3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies
- (2015) M.J. Ahn et al. EUROPEAN JOURNAL OF CANCER
- Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
- (2015) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
- (2015) Qingbei Zeng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment
- (2015) David Ly et al. JOURNAL OF NEUROSURGERY
- Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease
- (2015) Petra Hoffknecht et al. Journal of Thoracic Oncology
- Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
- (2015) Javier Cortés et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
- (2015) Deepa Rangachari et al. LUNG CANCER
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases
- (2015) J. J. Harding et al. ONCOLOGIST
- Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting
- (2015) Geoffrey T. Gibney et al. Cancer Medicine
- 64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
- (2015) Hiroaki Kurihara et al. EJNMMI Research
- On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases
- (2014) C. Gaudy-Marqueste et al. ANNALS OF ONCOLOGY
- Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
- (2014) I. E. Krop et al. ANNALS OF ONCOLOGY
- Metastatic breast cancer subtypes and central nervous system metastases
- (2014) C. Aversa et al. BREAST
- Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib
- (2014) L. Peuvrel et al. JOURNAL OF NEURO-ONCOLOGY
- LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases
- (2014) Kamran A. Ahmed et al. JOURNAL OF NEURO-ONCOLOGY
- Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases
- (2014) Siow Ming Lee et al. JNCI-Journal of the National Cancer Institute
- A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
- (2014) Yuankai Shi et al. Journal of Thoracic Oncology
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
- (2014) Shirish M Gadgeel et al. LANCET ONCOLOGY
- Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2014) Luca Gianni et al. LANCET ONCOLOGY
- Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases
- (2014) Marcin R. Dzienis et al. MELANOMA RESEARCH
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
- (2013) S. Dearden et al. ANNALS OF ONCOLOGY
- A Phase II Trial of Sunitinib in Patients With Renal Cell Cancer and Untreated Brain Metastases
- (2013) Christine Chevreau et al. Clinical Genitourinary Cancer
- Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study
- (2013) Reinhard Dummer et al. EUROPEAN JOURNAL OF CANCER
- A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320
- (2013) Paul W. Sperduto et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Severe Liver and Skin Toxicity After Radiation and Vemurafenib in Metastatic Melanoma
- (2013) Christopher J. Anker et al. JOURNAL OF CLINICAL ONCOLOGY
- Prolonged Survival of a Patient With Papillary Renal Cell Carcinoma and Brain Metastases Using Pazopanib
- (2013) Corbin Jacobs et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer
- (2013) James W. Welsh et al. JOURNAL OF CLINICAL ONCOLOGY
- Vemurafenib and radiation therapy in melanoma brain metastases
- (2013) Ashwatha Narayana et al. JOURNAL OF NEURO-ONCOLOGY
- Gamma Knife surgery for the treatment of 5 to 15 metastases to the brain
- (2013) David J. Salvetti et al. JOURNAL OF NEUROSURGERY
- 64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer
- (2013) K. Tamura et al. JOURNAL OF NUCLEAR MEDICINE
- Clinical Impact of Continued Crizotinib Administration after Isolated Central Nervous System Progression in Patients with Lung Cancer Positive for ALK Rearrangement
- (2013) Masayuki Takeda et al. Journal of Thoracic Oncology
- Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement
- (2013) Denis Maillet et al. Journal of Thoracic Oncology
- Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma
- (2013) T. Iuchi et al. LUNG CANCER
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor
- (2013) Eamon M. Berge et al. SEMINARS IN ONCOLOGY
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- Vemurafenib and Radiosensitization
- (2013) Lise Boussemart et al. JAMA Dermatology
- Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803)
- (2012) Y.- L. Wu et al. ANNALS OF ONCOLOGY
- Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype
- (2012) Nils D. Arvold et al. BREAST CANCER RESEARCH AND TREATMENT
- Isolated central nervous system progression on Crizotinib
- (2012) Stephen G. Chun et al. CANCER BIOLOGY & THERAPY
- Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK-Positive Non-Small Cell Lung Cancer
- (2012) J. Tanizaki et al. CLINICAL CANCER RESEARCH
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
- (2012) Thomas Bachelot et al. LANCET ONCOLOGY
- Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation
- (2012) S.J. Park et al. LUNG CANCER
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases
- (2012) Hsin-Lun Lee et al. Radiation Oncology
- NRAS mutation status is an independent prognostic factor in metastatic melanoma
- (2011) John A. Jakob et al. CANCER
- Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER
- (2011) A. M. Brufsky et al. CLINICAL CANCER RESEARCH
- Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
- (2011) Gianfranco A. Pesce et al. EUROPEAN JOURNAL OF CANCER
- RASMutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
- (2011) Patrick A. Oberholzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance to BRAF Inhibition in Melanomas
- (2011) David B. Solit et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032
- (2011) Maria J. Sambade et al. RADIOTHERAPY AND ONCOLOGY
- Predictive Factors for the Development of Brain Metastasis in Advanced Unresectable Metastatic Melanoma
- (2010) Agop Y. Bedikian et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
- (2010) R. Porta et al. EUROPEAN RESPIRATORY JOURNAL
- Gamma knife surgery for 1–10 brain metastases without prophylactic whole-brain radiation therapy: analysis of cases meeting the Japanese prospective multi-institute study (JLGK0901) inclusion criteria
- (2010) Toru Serizawa et al. JOURNAL OF NEURO-ONCOLOGY
- Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth
- (2010) Josette Carnahan et al. MOLECULAR CANCER THERAPEUTICS
- EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer
- (2010) A. F. Eichler et al. NEURO-ONCOLOGY
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS
- (2009) Daisy Wing-Sze Wong et al. CANCER
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
- (2009) N. U. Lin et al. CLINICAL CANCER RESEARCH
- Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Central Nervous System Metastases
- (2009) Brian Leyland-Jones JOURNAL OF CLINICAL ONCOLOGY
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis
- (2009) Jeong-Eun Kim et al. LUNG CANCER
- Non-solid oncogenes in solid tumors:EML4-ALKfusion genes in lung cancer
- (2008) Hiroyuki Mano CANCER SCIENCE
- Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response
- (2008) C.-H. Gow et al. CLINICAL CANCER RESEARCH
- Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
- (2008) P MEDINA et al. CLINICAL THERAPEUTICS
- An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N- -6-[5-( methyl)-2-furyl]-4-quinazolinamine; GW572016)
- (2008) J. W. Polli et al. DRUG METABOLISM AND DISPOSITION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now